Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
No pharmaceutical company, no academic medical center, and no government agency has found the existing preclinical data compelling enough to fund a rigorous human trial in over 30 years
Studies showed: Healing acceleration in NSAID-induced gastric ulcers (rat models) Protection against ethanol and stress-induced mucosal damage Effective healing of inflammatory bowel disease lesions in experimental colitis Fistula healing demonstrated in various gastrointestinal models Cardiovascular Research Vascular Injury and Protection Studies Research on component peptides examined effects in various cardiovascular scenarios: Improved healing in vascular anastomosis models Protection against arrhythmias in toxicity models Enhanced angiogenesis and collateral circulation development Potential cardioprotective effects in ischemia-reperfusion models Critical Research Gap: While individual components show promising effects across multiple tissue types, comprehensive studies specifically examining GLOW Blend as a combined formulation remain limited
The vote did not approve BPC-157 or show that it treats ulcerative colitis, Crohn's disease or "gut healing"
A board-certified physician reviews your health history and goals
321 , F50F68 (2021)
